Trevena Inc. (TRVN)
Factsheet
-
Market Capitalisation
$12 Mln
-
-
Price to Earnings Ratio
--
-
12 Month Earnings
$-30 Mln
Trevena Inc. (TRVN) Share Price
NASDAQ
$0.64
As on 07-Dec-2023 09:42 EST
$0.02
•
3.09%
As on 07-Dec-2023 09:42 EST
-
Prev Close
$0.63
-
Day's Open
$0.63
-
Today's High
$0.64
-
Today's Low
$0.63
-
Today's Volume
7,887
-
52 Week range
$0.51 - 3.28
Please wait...
Trevena Inc. (TRVN) Stock Performance
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Trevena (TRVN)
| -54.94 | 11.30 | -35.56 | -75.02 | -77.81 | -47.56 | -- |
|
S&P BSE Sensex
| 14.27 | 7.02 | 5.53 | 11.01 | 15.54 | 14.51 | 12.72 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
As on 07-Dec-2023
| #As on
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Trevena (TRVN)
| -90.19 | -72.76 | 154.49 | 95.56 | -72.93 | -72.79 | -44.00 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
Valuation
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Growth & Efficiency
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Solvency
Is there a threat to this company's solvency in the future?
Financial Manipulation
Can creative accounting be detected through the financial numbers?
Trevena Inc. (TRVN) Peer Comparison
Please wait...
Valuation Chart of Trevena Inc. (TRVN)
Please wait...
Please wait...
Financials
Please wait...
Please wait...
Please wait...
Shareholding Pattern
Other details of Trevena Inc. (TRVN)
Pres, CEO & Director
Ms. Carrie L. Bourdow
Sr. VP & CFO
Mr. Barry Shin
Headquarters
Chesterbrook, PAWebsite
https://www.trevena.comFAQs for Trevena Inc. (TRVN)
What is the total asset value of Trevena Inc. (TRVN)?
The total asset value of Trevena Inc. (TRVN) stood at $ 46 Mln as on 31-Mar-23
What is the current share price of Trevena Inc. (TRVN)?
The share price of Trevena Inc. (TRVN) is $0.64 (NASDAQ) as of 07-Dec-2023 09:42 EST. Trevena Inc. (TRVN) has given a return of -77.81% in the last 3 years.
What is the market cap of Trevena Inc. (TRVN)?
Trevena Inc. (TRVN) has a market capitalisation of $ 12 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
What is the current PB ratio of Trevena Inc. (TRVN)?
The P/B ratio of Trevena Inc. (TRVN) is 0.57 times as on 02-Jun-2023, a -0.78% premium to its peers’ median range of 2.54 times.
What is the current P/E ratio of Trevena Inc. (TRVN)?
Since, TTM earnings of Trevena Inc. (TRVN) is negative, P/E ratio is not available.
How can you buy shares of Trevena Inc. (TRVN)?
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Trevena Inc. (TRVN) and enter the required number of quantities and click on buy to purchase the shares of Trevena Inc. (TRVN).
What is the main business of Trevena Inc. (TRVN)?
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Who are the promoters/managers of Trevena Inc. (TRVN)?
The CEO & director of Ms. Carrie L. Bourdow. is Trevena Inc. (TRVN), and CFO & Sr. VP is Mr. Barry Shin.
What is the total promoter pledging in Trevena Inc. (TRVN)?
The promoters of Trevena Inc. (TRVN) have pledged 0% of the total equity as on Mar-23.
Who are the competitors of Trevena Inc. (TRVN)?
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
483
|
|
|
9
|
|
|
7
|
|
|
4
|
What are the key ratios of Trevena Inc. (TRVN)?
| Trevena Inc. (TRVN) | Ratios |
|---|---|
|
Return on equity(%)
|
-271.18
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
1.33
|
|
Dividend yield(%)
|
0
|
Is the Trevena Inc. (TRVN) profitable?
No, TTM profit after tax of Trevena Inc. (TRVN) was $-30 Mln.
Edit
Please wait...
Please wait...
Key Facts
-
Market cap
$11.85 Mln
-
Revenue (TTM)
$-0.43 Mln
-
Earnings (TTM)
$-30.28 Mln
-
Cash
$27.44 Mln
-
Total Debt
$19.60 Mln
- Insider's Holding 3.34%
-
Liquidity
High
-
52 Week range
$0.51 - 3.28
-
Shares outstanding
10,969,000
-
10 Years Aggregate:
CFO: $-439.01 Mln
EBITDA: $-479.56 Mln
Net Profit: $-488.76 Mln
About The Company
- IPO Date 31-Jan-2014
- Pres, CEO & Director Ms. Carrie L. Bourdow
- Sr. VP & CFO Mr. Barry Shin
-
Listing
NASDAQ: TRVN
- Country United States
-
Headquarters
Chesterbrook, PA
-
Website
https://www.trevena.com
-
Business
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G... protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Read more
